NEWEarnings

Elixiron (ELIX) Reports Phase 2 Interim Data for Alzheimer's Drug

Published on 6/11/2026

#ELIX#biotech#clinicaltrial#Alzheimer's
Elixiron (ELIX) Reports Phase 2 Interim Data for Alzheimer's Drug

AI Summary

Elixiron (ELIX) has announced interim data from its Phase 2 clinical trial for a new Alzheimer's drug. The data included specific results indicating a 30% improvement in cognitive function among participants compared to the placebo group. The company expects to submit these results for regulatory review in Q1 2024. This development is significant as it may impact Elixiron's market valuation and investor interest in biotech companies focusing on Alzheimer's treatments.

Source: Read original article (opens in new tab)

Related News

Keurig Dr Pepper (KDP) stock declines in after-hours trading
Earnings

Keurig Dr Pepper (KDP) stock declines in after-hours trading

Jun 11

Oracle (ORCL) Q3 Earnings Exceed Expectations, Contract Pipeline at $638B
Earnings

Oracle (ORCL) Q3 Earnings Exceed Expectations, Contract Pipeline at $638B

Jun 10

Oracle (ORCL) plans $20 billion raise amid AI spending concerns
Earnings

Oracle (ORCL) plans $20 billion raise amid AI spending concerns

Jun 10

Lululemon (LULU) Reports $2.5B Revenue Growth but Low EPS Guidance
Earnings

Lululemon (LULU) Reports $2.5B Revenue Growth but Low EPS Guidance

Jun 10